Nasdaq Welcomes NovoCure Limited to The Nasdaq Stock Market


NEW YORK, Oct. 02, 2015 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of NovoCure Limited (Nasdaq:NVCR) commenced on The Nasdaq Stock Market on October 2, 2015.

A photo accompanying this release is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/85f1ec95-8e1c-43e2-95e4-f690ed69b36e

NovoCure Limited is a commercial-stage oncology business pioneering a novel therapy for solid tumors called Tumor Treating Fields or TTFields. TTFields is a low toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on key molecules inside cancer cells, disrupting the basic machinery necessary for normal cell division, leading to cancer cell death. Headquartered in the Bailiwick of Jersey, Novocure has operations in the United States, Switzerland, Germany, Japan and Israel and has treated more than 1,640 patients to date with TTFields therapy.

“Novocure’s non-invasive, wearable TTFields therapy represents a completely new modality for treating cancer and we are excited to welcome Novocure to our family of listed companies,” said Nelson Griggs, Executive Vice President, Listing Services, Nasdaq. “We look forward to supporting its success and growth in the future.”

By listing on Nasdaq, NovoCure Limited joins many of the world’s largest and most revolutionary companies. Nasdaq is the exchange of choice for 78 percent of healthcare companies that have listed on the U.S. markets year-to-date.

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of approximately $9.5 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.  

NDAQG

 


            
NovoCure Limited Opening Bell

Contact Data